In the Press
Coverage from journalists, analysts, and ecosystem partners on how Assyro is rebuilding regulatory submissions for pharma, biotech, and medical device teams.
“The path from clinical trials to FDA approval is paved with paperwork — and formatting mistakes can cause significant delays.”
“Pharmaceutical companies spend billions annually on regulatory compliance, with submission preparation often taking months of painstaking documentation work.”
“Antler Toronto's latest cohort is producing the next wave of AI-native companies — including Assyro, building for pharma regulatory.”
Coverage links are curated from publicly indexed sources and updated on a rolling basis.